Clinical trials · North Carolina
Cancer clinical trials in North Carolina
We’re tracking 622 recruiting cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT06900595RecruitingPhase 2
Cabozantinib with immunotherapy for advanced adrenal cancer
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
Raleigh, North CarolinaAges 12 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Durham, North CarolinaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Durham, North CarolinaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Pinehurst, North CarolinaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Chapel Hill, North CarolinaAges 18 years+ - NCT06634381Recruiting
Fatigue in cancer survivors: A study to learn more
This study asks cancer survivors about their fatigue (tiredness, weakness, or exhaustion) to better understand it. It involves filling out questionnaires and maybe an interview. Your participation helps doctors learn how to support survivors like you.
Charlotte, North CarolinaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Durham, North CarolinaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Charlotte, North CarolinaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Concord, North CarolinaAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Raleigh, North CarolinaAges 18 years+ - NCT06567704Recruiting
Fatigue from immunotherapy in lung cancer: a patient interview study
This study aims to understand how maintenance immunotherapy affects fatigue in people with non-small cell lung cancer. Researchers will talk with patients to learn about their experiences.
Charlotte, North CarolinaAges 18 years+ - NCT06551116Recruiting
Better HER2 testing for HER2-low breast cancer on Enhertu
This study looks at using a more detailed lab test to measure HER2 levels in people with HER2-low metastatic breast cancer who are starting or have just started treatment with Enhertu. The goal is to see if this test can help doctors better understand who might benefit from Enhertu.
Chapel Hill, North CarolinaAges 18 years+ - NCT06497569Recruiting
Support program for people with gastroesophageal cancer
This study offers remote nutrition guidance and support for people with gastroesophageal cancer who are starting chemotherapy or radiation. The goal is to help you stay strong and manage side effects during treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT06457919RecruitingPhase 1/Phase 2
Tinengotinib with standard treatments for advanced prostate cancer
This study tests a new drug called tinengotinib combined with standard treatments for men with advanced prostate cancer that has stopped responding to abiraterone or enzalutamide. The goal is to see if the combination can help control the cancer.
Durham, North CarolinaAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Chapel Hill, North CarolinaAges Up to 12 months - NCT06252545Recruiting
Improving clinical trial engagement for pancreatic cancer with an app
This study is about improving how Black individuals with pancreatic cancer connect with clinical trials, using a smartphone app. You would participate in a 1-hour interview to share your experiences.
Chapel Hill, North CarolinaAges 18 years+ - NCT06205485RecruitingPhase 3
Chemotherapy and surgery vs chemoradiation for rectal cancer
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
Greenville, North CarolinaAges 18 years+ - NCT06158139RecruitingPhase 1
Testing modified immune cells for pancreatic cancer
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
Chapel Hill, North CarolinaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Jacksonville, North CarolinaAges 18 years+ - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
Durham, North CarolinaAges 18 years+ - NCT05620329Recruiting
Pleural fluid registry for drainage in adults
This registry collects information from adults who have fluid around the lungs (pleural effusion) and need clinically indicated drainage because of infection or cancer. It helps researchers better understand these conditions and improve future care.
Chapel Hill, North CarolinaAges 18 years+ - NCT06096038RecruitingPhase 1
CAR-T cell therapy for head and neck cancer
This trial tests a new treatment using your own immune cells (CAR-T cells) to target a protein called CSPG4 found on head and neck cancer cells. It is for people whose cancer has come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+
Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 6 studies
- UNC Lineberger Comprehensive Cancer Center · 5 studies
- FirstHealth of the Carolinas · 3 studies
- Atrium Health Wake Forest Baptist · 2 studies
- Carolinas Medical Center/Levine Cancer Institute · 2 studies
- East Carolina University · 2 studies
- Levine Cancer Institute · 2 studies
- Wake Forest University Health Sciences · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in North Carolina?
- Yes. We're currently tracking 622 recruiting cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.